Rhythm Pharmaceuticals, Inc. (BMV:RYTM)

Mexico flag Mexico · Delayed Price · Currency is MXN
1,866.76
-158.24 (-7.81%)
At close: Nov 18, 2025
94.86%
Market Cap 127.01B
Revenue (ttm) 3.20B
Net Income (ttm) -3.63B
Shares Out n/a
EPS (ttm) -56.97
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 599
Average Volume 3,380
Open 1,866.76
Previous Close 2,025.00
Day's Range 1,866.76 - 1,866.76
52-Week Range 1,800.00 - 2,025.00
Beta n/a
RSI 78.94
Earnings Date Feb 24, 2026

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company’s lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 de... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2008
Employees 283
Stock Exchange Mexican Stock Exchange
Ticker Symbol RYTM
Full Company Profile

Financial Performance

In 2024, Rhythm Pharmaceuticals's revenue was $130.13 million, an increase of 68.06% compared to the previous year's $77.43 million. Losses were -$264.57 million, 43.3% more than in 2023.

Financial numbers in USD Financial Statements

News

There is no news available yet.